ISIS Pharm., Inc

Article Abstract:

Isis Pharmaceuticals is engaged in the discovery and development of antisense drugs. A comparative analysis of the company sales and financial details of from 1991 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.

Author: Ferrara, J. Susan

Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004

Pharmaceutical preparations, Isis Pharmaceuticals Inc., ISIS

User Contributions:

Comment about this article or add new information about this topic:

Vertex Pharmaceuticals Inc

Article Abstract:

Vertex Pharmaceuticals Inc. is selling its biochemical and cellular assay capabilities and commercial portfolio of properties to Invitrogen to concentrate on discovery and development of drugs. Shares have risk but also appreciation potential out to 2006-2008.

Author: Ferrara, J. Susan

Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003

Forecasts, trends, outlooks, Financial management, Labor Distribution by Employer, Finance, Company investment, Investments, Statistics, Company business forecast/projection, Company forecasts, Vertex Pharmaceuticals Inc., VRTX

User Contributions:

Comment about this article or add new information about this topic:

Subjects list: United States, Pharmaceutical industry, Securities, Company sales and earnings, Company earnings/profit, Company securities

Similar abstracts:

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.

Abstracts

Business, general

ISIS Pharm., Inc

Vertex Pharmaceuticals Inc